Inhibition of mouse B16 melanoma by sodium butyrate correlated to tumor associated macrophages differentiation suppression

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 3, 2015, Pages 4170-4174

  Xiong, Fen ^a   Mou, Yun Zhu ^a   Xiang, Xiao Yan ^a  

^a AFFILIATED HOSPITAL OF NORTH SICHUAN MEDICAL COLLEGE   (China)

Author keywords

B16; Sodium butyrate (NaB); TAMs

Indexed keywords

BUTYRIC ACID; CD11B ANTIGEN; INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; MELANOMA B16; MOUSE; MTT ASSAY; NONHUMAN; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; WESTERN BLOTTING;

EID: 84929359388     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Demary K, Wong L, Spanjaard RA. Effects of retinoic acid and sodium butyrate on gene expression, histone acetylation and inhibition of proliferation of melanoma cells. Cancer Lett 2001; 163: 103-108.
2. Fernandes BF, Maloney SC, Antecka E, Di Cesare S, Granner T, Burnier MN Jr. Sodium Butyrate (NaB) Induces KAI-1 Expression And Apoptosis In Uveal Melanoma. Invest Ophtalmol Vis Sci 2011; 52: 1447.
3. Jazirehi AR. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy. Anticancer Drugs 2010; 21: 805-813.
4. Chen W, Wei F, Xu J, Wang Y, Chen L, Wang J, Guan X. Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line. Intl J Mol Med 2011; 28: 985.
5. Bandyopadhyay D, Mishra A, Medrano EE. Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway. Cancer Res 2004; 64: 7706-7710.
6. Kim YH, Park JW, Lee JY, Kwon TK. Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. Carcinogenesis. 2004; 25: 1813-1820.
7. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, Rimoldi M, Biswas SK, Allavena P, Mantovani A.Macrophage polarization in tumour progression. Semin Cancer Biol 2008; 18: 349-55.
8. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549-555.
9. Marthyn P, Beuscart A, Coll J, Moreau-Gachelin F, Righi M. DMSO Reduces CSF-1 Receptor Levels and Causes Apoptosis in v-myc immortalizedmouse macrophages. Exp Cell Res 1998; 243: 94-100.
10. Takasaki S, Leive L. Induction by dimethyl sulfoxide of Fc fragment-mediated phagocytosis in the mouse macrophage-like cell line P388D1. Proc Natl Acad Sci U S A 1982; 79: 4980-4.
11. Medina V, Edmonds B, Young GP, James R, Appleton S, Zalewski PD. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res 1997; 57: 3697-3707.
12. Qiu L, Burgess A, Fairlie DP, Leonard H, Parsons PG, Gabrielli BG. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell 2000; 11: 2069-2083.
13. Zhang XD, Gillespie SK, Borrow JM, Hersey P. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol Cancer Ther 2004; 3: 425-435.
14. Flørenes VA, Skrede M, Jørgensen K, Nesland JM. Deacetylase inhibition in malignant melanomas: impact on cell cycle regulation and survival. Melanoma Res 2004; 14: 173-181.
15. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005; 45: 495-528.
16. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002; 8: 718-728.